EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Fate Therapeutics's enterprise value is $-70.38 Mil.
Fate Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 was $-177.57 Mil. Therefore, Fate Therapeutics's EV-to-EBITDA for today is 0.40.
The historical rank and industry rank for Fate Therapeutics's EV-to-EBITDA or its related term are showing as below:
FATE'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -78.24 Med: -4.5 Max: 0.44
Current: 0.4
During the past 13 years, the highest EV-to-EBITDA of Fate Therapeutics was 0.44. The lowest was -78.24. And the median was -4.50.
FATE's EV-to-EBITDA is ranked better than 81.42% of 479
companies
in the Biotechnology industry
Industry Median: 7.43
vs FATE: 0.40
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Fate Therapeutics EV-to-EBITDA Historical Data
The historical data trend for Fate Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Fate Therapeutics's EV-to-EBITDA
For the Biotechnology subindustry, Fate Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fate Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fate Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Fate Therapeutics's EV-to-EBITDA falls into.
Fate Therapeutics's current Enterprise Value is $-70.38 Mil.
Fate Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-177.57 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Fate Therapeutics's PE Ratio (TTM) for today is calculated as:
Fate Therapeutics's share price for today is $1.12.
Fate Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.650.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Thank you for viewing the detailed overview of Fate Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FATE has been successfully added to your 